TABLE 2.
Comparison of treatment modalities: success versus failurea.
| Antibiotic | M. abscessus pulmonary disease | M. abscessus subsp. abscessus pulmonary disease | M. abscessus subsp. massiliense pulmonary disease | |||||||||
| Total (n = 244) | Success (n = 110) | Failure (n = 134) | P-value | Total (n = 185) | Success (n = 62) | Failure (n = 123) | P-value | Total (n = 59) | Success (n = 48) | Failure (n = 11) | P-value | |
| Clarithromycin | 199 | 86(78.2) | 113(84.3) | 0.218 | 149 | 44(71.0) | 105(85.4) | 0.020 | 50 | 42(87.5) | 8(72.7) | 0.347 |
| Azithromycin | 61 | 32(29.1) | 29(21.6) | 0.181 | 47 | 23(37.1) | 24(19.5) | 0.010 | 14 | 9(18.8) | 5(45.5) | 0.110 |
| Amikacin | 218 | 104(94.5) | 114(85.1) | 0.017 | 166 | 60(96.8) | 106(86.2) | 0.025 | 52 | 44(91.7) | 8(72.7) | 0.112 |
| Imipenem | 67 | 39(35.5) | 28(20.9) | 0.011 | 47 | 22(35.5) | 25(20.3) | 0.025 | 20 | 17(35.4) | 3(27.3) | 0.734 |
| Meropenem | 13 | 7(6.4) | 6(4.5) | 0.514 | 10 | 5(8.1) | 5(4.1) | 0.256 | 3 | 2(4.2) | 1(9.1) | 0.468 |
| Cefoxitin | 144 | 65(59.1) | 79(59.0) | 0.983 | 110 | 38(61.3) | 72(58.5) | 0.719 | 34 | 27(56.2) | 7(63.6) | 0.745 |
| Linezolidb | 38 | 24(21.8) | 14(10.4) | 0.015 | 27 | 15(24.2) | 12(9.8) | 0.009 | 11 | 9(18.8) | 2(18.2) | 1.000 |
| Tigecycline | 53 | 32(29.1) | 21(15.7) | 0.011 | 39 | 19(30.6) | 20(16.3) | 0.024 | 14 | 13(27.1) | 1(9.1) | 0.269 |
| Doxycycline | 30 | 10(9.1) | 20(14.9) | 0.167 | 23 | 6(9.7) | 17(13.8) | 0.420 | 7 | 4(8.3) | 3(27.3) | 0.112 |
| Minocycline | 22 | 10(9.1) | 12(9.0) | 0.971 | 15 | 4(6.5) | 11(8.9) | 0.558 | 7 | 6(12.5) | 1(9.1) | 1.000 |
| Moxifloxacinb | 53 | 28(25.5) | 25(18.7) | 0.200 | 34 | 13(21.0) | 21(17.1) | 0.519 | 19 | 15(31.2) | 4(36.4) | 0.734 |
| Levofloxacinb | 26 | 8(7.3) | 18(13.4) | 0.121 | 20 | 4(6.5) | 16(13.0) | 0.175 | 6 | 4(8.3) | 2(18.2) | 0.310 |
| Ciprofloxacin | 17 | 8(7.3) | 9(6.7) | 0.865 | 13 | 4(6.5) | 9(7.3) | 1.000 | 4 | 4(8.3) | 0(0) | 1.000 |
| Number of patients administered: | – | – | – | 0.810 | – | – | – | 0.148 | – | – | – | 0.367 |
| One parenteral drug | 15 | 6(5.5) | 9(6.7) | – | 9 | 1(1.6) | 8(6.5) | – | 6 | 5(10.4) | 1(9.1) | – |
| Two parenteral drugs | 161 | 70(63.6) | 91(67.9) | – | 124 | 38(61.3) | 86(69.9) | – | 37 | 32(66.7) | 5(45.5) | – |
| Three parenteral drugs | 62 | 31(28.2) | 31(23.1) | – | 47 | 21(33.9) | 26(21.1) | – | 15 | 10(20.8) | 5(45.5) | – |
| More than three parenteral drugs | 6 | 3(2.7) | 3(2.2) | – | 5 | 2(3.2) | 3(2.4) | – | 1 | 1(2.1) | 0(0) | – |
| Months of treatment | 25.6 (18.8, 37.8) | 20.7 | 30.0 | <0.001 | 27.7 (20.7, 40.8) | 23.4 | 30.0 | 0.001 | 20.2 (15.9, 29.8) | 18.0 | 28.0 | 0.179 |
| (16.2, 31.0) | (22.0, 43.3) | (18.1, 34.6) | (22.0, 44.0) | (15.9, 26.8) | (16.0, 43.0) | |||||||
| Surgical resection | 10 | 2 | 8 | 0.192 | 7 | 1 | 6 | 0.427 | 3 | 1 | 2 | 0.086 |
aData are the number (percentage; the number of patients who succeeded or failed treatment with the indicated drug divided by the total number of patients who succeeded or failed treatment) or median (interquartile range) of cases. Each antibiotic listed was included regardless of whether it was discontinued during the course of treatment. bAdministered orally and/or intravenously.